Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/3542
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSujai, P T-
dc.contributor.authorJoseph, M M-
dc.contributor.authorKarunakaran, V-
dc.contributor.authorSaranya, G-
dc.contributor.authorAdukkadan, R N-
dc.contributor.authorShamjith, S-
dc.contributor.authorThomas, R-
dc.contributor.authorNair, J B-
dc.contributor.authorSwathi, R S-
dc.contributor.authorMaiti, K K-
dc.date.accessioned2020-02-25T14:00:39Z-
dc.date.available2020-02-25T14:00:39Z-
dc.date.issued2019-01-22-
dc.identifier.citationACS Applied Bio Materials; 2(1):588-600en_US
dc.identifier.urihttps://pubs.acs.org/doi/pdf/10.1021/acsabm.8b00746-
dc.identifier.urihttp://10.10.100.66:8080/xmlui/handle/123456789/3542-
dc.description.abstractEffective treatment of malignant melanoma requires an appropriate combination of therapeutic intervention with long-term prognosis as it often survives by monotherapies. Herein, we report a novel melanoma-targeted theranostic nanoenvelope (MTTNe: ISQ@BSA-AuNC@AuNR@DAC@DR5) which has been constructed by assembling a bovine serum albumin (BSA) stabilized gold nanocluster on a gold nanorod (BSA-AuNC@AuNR), a three-in-one theranostic modality, i.e., photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy, tethered with a surface-enhanced Raman scattering (SERS) detection technique. The resultant MTTNe was coloaded with the melanoma-specific FDA approved drug dacarbazine (DAC) and a newly synthesized near-infrared (NIR) absorbing squaraine molecule ISQ that served partly as a photosensitizer and multiplex Raman reporter. Finally, a nanoenvelope was anchored with anti-DR5 monoclonal antibodies as a targeting motif for highly expressed melanoma-specific death receptors in malignant cells. Significant phototherapies of MTTNe were initiated upon an 808 nm single laser trigger which showed a synergistic effect of photothermal hyperthermia as well as singlet oxygen (1O2) driven photodynamic effect in the presence of ISQ followed by on-demand thermoresponsive drug release in the intracellular milieu. Moreover, a multiplex SERS spectral pattern of ISQ (1345 cm–1) and DAC (1269 cm–1) has been utilized for monitoring precise drug release kinetics and target-specific recognition on melanoma cells by Raman imaging. Therapeutic performance of the nanoenvelope was evaluated by in vitro cytotoxicity studies in human melanoma cells (A375) and confirmed the apoptotic phenomenon by molecular-level monitoring of intracellular SERS fingerprints. Finally, to address the biocompatibility of MTTNe, in vivo subacute toxicity was conducted on BALB/c mice. Hence, the current studies mark a footstep of a facile strategy for the treatment of melanoma by synergistic multimodal photothermal/photodynamic/chemotherapy.en_US
dc.language.isoenen_US
dc.publisherAmerican Chemical Societyen_US
dc.subjectgold nanorodsen_US
dc.subjectbiocompatibleen_US
dc.subjectphototherapiesen_US
dc.subjectchemotherapyen_US
dc.subjectSERSen_US
dc.subjectFDTD simulationsen_US
dc.titleBiogenic Cluster-Encased Gold Nanorods as a Targeted Three-in-One Theranostic Nanoenvelope for SERS-Guided Photochemotherapy against Metastatic Melanomaen_US
dc.typeArticleen_US
Appears in Collections:2019

Files in This Item:
File Description SizeFormat 
Biogenic Cluster-Encased Gold Nanorods as a Targeted_PT Sujai_Applied Bio Materials.pdf
  Restricted Access
12.71 MBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.